


**FIG 2** Clonality, copy number, and integration site of HTLV-1 in TL-Om1 cells. (A) HTLV-1 proviral copy number per cell was determined by FISH using an HTLV-1 full-genome probe. (i) Yellow signals indicate the HTLV-1 probe. Lower table shows the counts of HTLV-1 signals per cell. (ii) Vertical axis indicates percentage counts of each fraction in relation to total cells. Data were the results from two independent analyses. (B) Number of HTLV-1 integrated chromosomes was determined in metaphase cells with the HTLV-1 and 1q44 probes. (i, ii) Yellow signals indicate the HTLV-1 probe, and red signals indicate the 1q44 probe. All HTLV-1 signals were located on chromosome 1. HTLV-1 signals on chromosome 1 were positioned at 1p13. (C) Determination of the HTLV-1 integration site in TL-Om1 cells. (i) The 3' integration site was determined by Splinkerette PCR with an HTLV-1-specific primer. PCR products were subjected to agarose gel electrophoresis. (ii) BamHI- or XbaI-digested TL-Om1 genomes were self-ligated and subjected to inverse PCR with an HTLV-1-specific primer set. PCR products were subjected to agarose gel electrophoresis. (D) 5' and 3' HTLV-1 integration sites were determined by a sequencing analysis of DNA fragments from both Splinkerette and inverse PCR. (i) Normal human sequence; (ii) determined HTLV-1 integration site. HTLV-1 was inversely integrated at chromosome 1: NT\_077389, 164570 to 164576.

value of target gene primers from the average  $C_T$  value of RPPH1 primers (Table 1). The correction value was calculated as follows: correction  $C_T$  value = correction factor  $\times$  actual  $C_T$  value. By applying the correction factors, we reduced the limits of error of the  $C_T$  values to 0.1 cycles with normal PBMCs (data not shown).

**Digital PCR analysis.** Primers and probes for digital PCR analysis of HTLV-1 were previously reported (11, 15). In brief, the primers and probe for HTLV-1 were as follows: forward, 5'-CGGATACCCAGTCTACGTGTT-3'; reverse, 5'-CAGTAGGCGTGACGATGTA-3'; probe, FAM-5'-CTGTGTACAAGGCGACTGGTGC-3'-TAMRA (where FAM is 6-car-

boxylfluorescein and TAMRA is 6-carboxytetramethylrhodamine). The primers and probe for albumin were as follows: forward, 5'-TGTCATCTCTTGTGGGCTGT-3'; reverse, 5'-GGTTCTCTTCACTGACATCTGC-3'; probe, FAM-5'-CCTGTCATGCCACACAAATCTCTCC-3'-TAMRA. The mixture of primers and probe for RPPH1 was purchased from Applied Biosystems. The PCR mixture was prepared using 2 $\times$  digital droplet PCR (ddPCR) supermix for probes (Bio-Rad, Hercules, CA, USA). Droplets were prepared on a QX100 droplet generator (Bio-Rad). PCR was performed with a LifePro thermal cycler (Bio-Rad) and detected with a QX100 droplet reader (Bio-Rad). Data were means of triplicate analysis.



**FIG 3** Gene copy number of IC cellular genes for HTLV-1 qPCR. (A) The number of chromosomes in TL-Om1 and Jurkat cells at metaphase was counted. Horizontal line indicates the number of chromosomes per cell. (B) Representative FISH images of TL-Om1 and Jurkat cells at metaphase. Yellow and red arrows indicate signals for ALB and RPPH1 probes, respectively. Left panel shows three signals for ALB and four for RPPH1; right panel shows two signals for ALB and two for RPPH1. (C) Determination of the gene copy number of HTLV-1, RPPH1, and ALB genes by digital PCR. gDNA of TL-Om1 and Jurkat cells and of PBMCs from two healthy donors were subjected to digital PCR. Data show the absolute copy number of HTLV-1, RPPH1, and ALB genes per microgram of gDNA. Bars are means from triplicate analyses.

***In vitro* HTLV-1 infectivity test.** Frozen cells were thawed and immediately cultured for a week. Exponentially growing cells were used for the assay. Jurkat, TL-Om1, SLB1, and HUT102 cells were treated with 50  $\mu$ g/ml mitomycin C (Kyowa Hakkō Kirin, Tokyo, Japan) and incubated for 1 h at 37°C. After being washed twice with 2% FBS-PBS,  $1 \times 10^5$  cells were added to culture medium containing  $1 \times 10^6$  Jurkat cells. Mitomycin C was used to block the growth of ATL cell lines added to Jurkat cells. Cells were cocultured for 2 weeks and then subjected to qPCR to determine PVL, as described previously (11).

## RESULTS

**HTLV-1 infectivity in TL-Om1 cells.** We investigated the production potential of infective virus to ascertain the clonal stability of HTLV-1 integration *in vitro*. Mitomycin C-treated TL-Om1 cells were cocultured with Jurkat cells for 2 weeks. At the end of the 2 weeks, no HTLV-1 integration was observed in the Jurkat cells that were cocultured with TL-Om1 cells, while HTLV-1 integration was observed when Jurkat cells were similarly cocultured with SLB-1 and HUT102 cells (Fig. 1A). These findings suggested that the production of infective HTLV-1 particles from TL-Om1 cells was low or diminished; thus, the increase in copy number over the course of cell culture was thought to be negligible. If TL-Om1 cells had infectious potential, the clonality of HTLV-1 provirus in them would vary because of the mutual HTLV-1 infections between cells. To evaluate the clonality of HTLV-1 provirus in TL-Om1 cells, TL-Om1 gDNA was analyzed by Southern blotting. EcoRI-digested gDNA showed a single band, while PstI digestion produced five DNA bands that contained an HTLV-1 sequence

(Fig. 1B). Three of the five DNA bands were HTLV-1 internal sequences. The other two DNA bands contained either 5' or 3' HTLV-1 sequences ligated with the host genome (Fig. 1B). These fragment patterns indicated that HTLV-1 provirus integration in TL-Om1 cells was monoclonal.

**Determination of copy number and integration site of HTLV-1 provirus by FISH.** To confirm the clonality and copy number of HTLV-1 provirus and of IC genes in detail, we performed a FISH analysis. There were one or two signals of HTLV-1 provirus in the cells. The mean proviral copy number was calculated at 1.8 copies/cell from the count of signals with >250 cells in two independent analyses (Fig. 2Ai and ii). Double-staining of the TL-Om1 genome with both HTLV-1 and 1q44 probes in meta-

**TABLE 2** Gene copy number of IC genes determined by FISH

	Gene copy no.			
	TL-Om1 (20 analyzed cells)		Jurkat (20 analyzed cells)	
Karyotype	RPPH1 gene	ALB gene	RPPH1 gene	ALB gene
2N	0	0	20	20
3N	1	20	0	0
4N	19	0	0	0
Average	3.95	3	2	2
Ratio to the RPPH1 gene	1	0.76	1	1

TABLE 3 Summary of ratio of gene copy numbers to the RPPH1 gene

Method	Cell line	Gene copy no. ratio to the RPPH1 gene							
		RPPH1 gene	ALB gene	ACTB gene	CD81 gene	HBB gene	RAG-1 gene	HTLV-1 gene	LTR gene
FISH	TL-Om1	1.00	0.76					0.46	
	Jurkat	1.00	1.00						
Digital PCR	TL-Om1	1.00	0.74					0.51	
	Jurkat	1.00	0.86						
	PBMC1	1.00	1.09						
	PBMC2	1.00	0.99						
qPCR (plasmid)	TL-Om1	1.00	0.74					0.48	1.02
	Jurkat	1.00	0.92						
qPCR (gDNA)	TL-Om1	1.00	0.74	1.18	0.99	0.92	0.94		
	Jurkat	1.00	0.95	1.07	0.99	0.90	1.08		
	PBMC 1	1.00	0.99	1.00	0.98	0.99	1.00		
	PBMC 2	1.00	1.01	1.01	0.99	1.00	1.01		

phase showed that all HTLV-1 DNA signals were located on chromosome 1 (Fig. 2Bi). When the number of copies of chromosome 1 was 1, 2, 3, or 4 per cell, the number of HTLV-1 proviruses per cell was 1, 1, 2, and 2, respectively (data not shown). HTLV-1 signals on chromosome 1 were positioned on the band of 1p13 (Fig. 2Bii). These results correlated well with the Southern blotting results that showed monoclonal integration.

#### Confirmation of integration site of HTLV-1 in TL-Om1 cells.

To identify the integration site of monoclonal HTLV-1 provirus, Splinkerette PCR was performed with TL-Om1 gDNA. Two specific PCR products were obtained by gel electrophoresis (Fig. 2Ci). The DNA fragments were analyzed by direct sequencing. Sequencing analysis of the lower-molecular-weight DNA fragments (Fig. 2Ci, lower band) showed that they were provirus genomic sequences. Sequencing analysis of the higher-molecular-weight band showed that it contained host gDNA ligated to the 3' LTR of HTLV-1. We also performed inverse PCR with TL-Om1 gDNA that was digested with BamHI or XbaI followed by self-ligation. Single DNA bands were obtained from both BamHI and XbaI self-ligated templates (Fig. 2Cii). Sequencing analysis demonstrated that both bands contained the same sequences. A BLAST search revealed that the sequence was located on chromosome 1. The integration site was identified, and the HTLV-1 provirus was integrated inversely in between the CATATAT repetitive sequences at the region of NT\_077389 from nucleotides (nt) 164570 to 164576 on chromosome 1 (Fig. 2Di and ii).

We determined the full-length sequence of HTLV-1 provirus in TL-Om1 cells by genomic long PCR followed by direct sequencing. The length of HTLV-1 provirus was determined to be 8,941 bp (GenBank accession no. AB979451; see also Text S1 in the supplemental material). The percent identity to the HTLV-1 genomic sequence of the ATK-1 strain (accession no. J02029) was 98.7%. Compared with the full-length HTLV-1 genomic sequence of ATK-1, there was a 93-nt deletion in the *env* gene. The region that was deleted was equivalent to nt 5547 to 5669 of ATK-1. The deduced amino acid sequence of the deletion was 31 in-frame amino acids ( $\Delta$ 125–155 of Env). The deleted region was located on the receptor binding domain of Env (see Fig. S1 in the supplemental material).

#### Calculation of chromosome and gene copy numbers of HTLV-1, RPPH1, and ALB genes in TL-Om1 and Jurkat cells.

We counted the chromosome number in TL-Om1 and Jurkat cells by FISH analysis. Jurkat cells were analyzed as one of the control cell lines. The chromosome number differed from 78 to 83 in TL-Om1 cells (Fig. 3A). The mean chromosome number was estimated at 80.2, which indicated that the karyotype of TL-Om1 cells was about 4N. There were 45 or 46 chromosomes in Jurkat cells, indicating that their karyotype is near that of normal human diploid cells (Fig. 3A and B and Table 2).


The absolute gene copy number of HTLV-1 provirus and IC genes was measured using digital PCR. gDNA from TL-Om1 cells, Jurkat cells, and PBMCs from two healthy donors was subjected to digital PCR and used to calculate the copy numbers of these genes (Fig. 3C). Although the ALB-to-RPPH1 gene copy number ratios in the two PBMC samples were 1.09 and 0.99, the ALB-to-RPPH1 gene copy number ratio in TL-Om1 cells was low (ratio of 0.74) (Table 3). The provirus-to-RPPH1 gene copy number ratio in TL-Om1 cells was 0.51 (Table 3). These results were consistent with the provirus- and ALB-to-RPPH1 gene copy number ratios estimated by FISH, which were 0.46 and 0.76, respectively (Table 3). The usefulness of TL-Om1 as a reference standard is strongly supported by the consistent results from the FISH and digital PCR analyses (Table 4).

**Estimation of the gene copy number of HTLV-1 and IC genes by synchronized qPCR.** We previously developed a method to determine inherited allelic deletions by using qPCR with primer sets that can amplify fragments synchronously, even though the

TABLE 4 Absolute gene copy number per microgram gDNA determined by digital PCR

Cell line	Gene copy no./ $\mu$ g gDNA <sup>a</sup>		
	HTLV-1 gene	RPPH1 gene	ALB gene
TL-Om1	170,171.1	335,452.3	248,410.8
Jurkat	NT	434,529.6	373,423.9
PBMC1	NT	355,116.1	388,650.0
PBMC2	NT	397,260.3	394,520.5


<sup>a</sup> Data are means of triplicate analysis. NT, not tested.



**FIG 4** Estimation of gene copy number of IC genes in TL-Om1 cells by qPCR. gDNA of TL-Om1 and Jurkat cells and of PBMCs from two healthy donors was tested by qPCR with synchronous amplification primer sets for IC genes. (A)  $C_T$  scores (cycles) of each primer set for IC genes. Each dot indicates the mean from triplicate analyses. The  $C_T$  scores in the graph were the results of correction by the factors described in Table 1. (B) Estimated gene copy number of IC genes calculated using the difference in  $C_T$  scores from RPPH1. The copy numbers of IC genes of TL-Om1 and Jurkat cells were calculated based on FISH analysis for the RPPH1 gene. RPPH1 gene copy number from PBMCs was set as  $2N$ . Equation for the estimation of gene copy number was as follows: gene copy number ( $N$ ) = RPPH1 gene copy number determined by FISH analysis  $\times 2^{-\Delta C_T}$ ,  $\Delta C_T = C_T(\text{target gene}) - C_T(\text{RPPH1})$ .

target genes are different. The method shows that the difference in  $C_T$  value determines the difference in gene copy number. We used primer sets for HTLV-1 genes (LTR and coding regions) and ACTB, ALB, CD81, HBB, and RAG-1 IC genes (Table 1). To increase the specificity, we used primer correction factors, which compensate for the slight difference in PCR amplification efficiency between different primers for target genes. As shown in Fig. 4A, TL-Om1 and Jurkat cells did not show the complete synchronized amplifications that were observed in normal PBMCs. By setting the PCR amplification efficiency of all primer sets per cycle

to approximately 2-fold, the ratio of the gene copy number against the RPPH1 gene was estimated using the difference in the mean  $C_T$  scores of the IC gene primer sets from the mean of those for the RPPH1 gene. The ratios of the gene copy number of the ALB gene to that of the RPPH1 gene in TL-Om1 and Jurkat cells were 0.74 and 0.92, respectively (Table 3). When the copy number of the RPPH1 gene in TL-Om1 cells was set at 3.95, which was determined by FISH analysis, the copy number of the IC genes was at least 2.9 (ALB gene) and at most 4.7 (ACTB gene) (Fig. 4B and Table 3).



**FIG 5** Estimation of the HTLV-1 gene copy number in TL-Om1 cells by synchronized qPCR. gDNA of TL-Om1 and Jurkat cells and of PBMCs from two healthy donors was tested for qPCR with synchronous amplification primer sets for HTLV-1, RPPH1, and ALB genes. (A) Construction of control plasmid with a single copy of each target sequence; (B) data indicate  $C_T$  scores of HTLV-1, RPPH1, and ALB genes for control plasmid at 1 pg, 100 fg/reaction, and for TL-Om1 and Jurkat cells. qPCR with the plasmid showed synchronous amplification of all primer sets. Each dot indicates the mean from triplicate analyses. The  $C_T$  scores in the graph are the results of correction by the factors described in Table 1. (C) Estimated HTLV-1 and ALB gene copy number in TL-Om1 and Jurkat cells. Data were estimated using the difference in  $C_T$  scores between target genes and RPPH1 genes.

Additionally, we tried to determine the HTLV-1 copy number in TL-Om1 cells using a synchronized qPCR method. We prepared a plasmid that had one copy of every target PCR amplicon (Fig. 5A). The plasmid had the same copy number as all the target regions. Using the plasmid as a template, we performed qPCR and confirmed the synchronized amplification of primer sets for HTLV-1, RPPH1, and ALB genes (Fig. 5B). The difference in mean  $C_T$  scores for the HTLV-1 gene to the RPPH1 gene was 1.05 cycles on average in TL-Om1 cells (Fig. 5C and Table 3). As with the sequencing analysis, use of the synchronized qPCR method also estimated the copy number of the LTR to be 4.01, indicating that TL-Om1 cells have two LTRs (Fig. 5C and Table 3).

**Comparison of HTLV-1 copy number from different calculation methods.** We compared the results of HTLV-1 and ALB gene copy number obtained from FISH, digital PCR, and synchronized qPCR. The copy number ratios of the HTLV-1 gene to the RPPH1 gene in TL-Om1 cells were 0.46, 0.51, and 0.48, from FISH, digital PCR, and synchronized qPCR, respectively, and those for the ALB gene were 0.76, 0.74, and 0.74 (Fig. 6 and Table 3). The results from these varied assays strongly support one another, indicating that TL-Om1 cells are suitable for use as a reference material for HTLV-1 qPCR.

**DISCUSSION**

Recently, NAT reference materials have been established for the safety of blood and blood products, such as international standards for HIV, hepatitis B virus, and hepatitis C virus (22–24). These materials have been frequently used for the purpose of calibration and validation of test systems, preparation of secondary reference materials, and comparison of multicenter results, which have helped improve the consistency of the results. Most international standards for blood-transmitted viruses use plasma from infected human blood, because the test target is extracted from human plasma. With regard to HTLV-1 NAT, it may be better to use a cell line as a reference material to standardize the qPCR results, because this test uses cells obtained from peripheral blood. An example of NAT reference material using cell lines is reported in a test for quantitation of BCR-ABL mRNA. Panels of K562 cells combined with HL60 cells were set as standards, which have been approved by the WHO Expert Committee of Biological Standardization (25). Although a variety of cell lines harboring HTLV-1 provirus in their genomes has been established, detailed characterization of the candidate cell lines with regard to their suitability as reference materials for HTLV-1 NATs has not yet been per-




FIG 6 HTLV-1- and ALB-to-RPPH1 gene copy number ratios. (A) Comparison of the HTLV-1- and ALB-to-RPPH1 gene copy number ratios determined by FISH, digital PCR, and qPCR. Data indicate percentages of gene copy number ratio to the RPPH1 gene.

formed. Among the HTLV-1 cell lines, TL-Om1 is well known to be latently infected with HTLV-1 and is thought to be stable for HTLV-1 clonality (17, 26). Transcription from HTLV-1 provirus in TL-Om1 cells is blocked by the highly methylated LTR (27).

In this study, we evaluated the distinct genomic properties of HTLV-1 and IC genes in TL-Om1 cells with regard to their suitability as reference materials for HTLV-1 NATs. Precise information about HTLV-1 infectivity, karyotype, and absolute copy number of HTLV-1 and cellular control genes of TL-Om1 is useful for applying TL-Om1 as a reference material for HTLV-1 qPCR. As such, for this use, TL-Om1 has advantages over other cell lines, such as the human ATL cell line MT2 and the rat T-cell line TARL-2. A recent study of HTLV-1 testing in Japanese blood donor screening revealed that virus prevalence is not limited to areas where HTLV-1 is endemic but has shifted to the entire country, especially the Tokyo metropolitan area (6). Nationwide HTLV-1 tests have been performed on pregnant women in Japan since the end of 2010. The frequent occurrence of seroindeterminate results after Western blotting is one weakness of the HTLV-1 antibody tests. HTLV-1 qPCR is thought to be a solution for decreasing the number of seroindeterminate results; therefore, an accurate measurement of HTLV-1 proviral DNA by qPCR is needed. Additionally, a PVL value of >4% in PBMCs is reported to be a risk factor for ATL development from HTLV-1 asymptomatic carriers, which emphasizes the importance of measuring PVL by qPCR (7). PVL monitoring also provides a risk indicator for HAM/TSP (8).

An attempt to minimize the differences between laboratories by using a common plasmid that included the pX region has been reported. When standard curves were constructed by utilizing the common plasmid in all participating laboratories, the differences in median intralaboratory coefficient of variation (CV) could be reduced by about half (16). Although the attempt worked well among participating laboratories with in-house qPCR methods, the transferability of utilizing common plasmids for standard curves to other methods for PVL determination, for example, digital PCR, is uncertain.

To standardize HTLV-1 qPCR, we advocate the use of TL-Om1 cells with finely elucidated HTLV-1 genomic information as reference material. A previous report showed that PVL values of males and females, on average, are 1.39% and 2.10%, respectively (7). Thus, a dilution or a serial dilution of TL-Om1 with PBMCs or Jurkat cells at a PVL value of around 2% would be an appro-

propriate material for the standardization of HTLV-1 qPCR. These kinds of references can be easily prepared, because the absolute gene copy number is determined from the dilution rate of TL-Om1. TL-Om1 cells were also used as a control in a deep-sequencing-based method for the quantification of the clone size of HTLV-1-infected cells in HTLV-1 carrier or ATL patients (28).

We conclude that TL-Om1 cells can be used as a useful reference material for HTLV-1 NATs. By using TL-Om1 cells, researchers will be able to define the exact values of HTLV-1 by quantifying the copy numbers of provirus and IC genes. In the future, we hope that other laboratories will utilize the features of TL-Om1 cells to standardize the HTLV-1 qPCR.

#### ACKNOWLEDGMENTS

This work was supported by grants-in-aid for scientific research and by Health and Labor Sciences research grant H23-shinkou-ippan-016 from the Ministry of Health, Labor and Welfare of Japan.

We thank all the members of the HTLV-1 qPCR standardization group for their useful discussions about this research.

We declare that we do not have any competing interests.

Ethical approval was not required for this study.

#### REFERENCES

- Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, Shirakawa S, Miyoshi I. 1981. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. *Proc Natl Acad Sci U S A* 78:6476–6480. <http://dx.doi.org/10.1073/pnas.78.10.6476>.
- Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. 1980. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc Natl Acad Sci U S A* 77:7415–7419. <http://dx.doi.org/10.1073/pnas.77.12.7415>.
- Watanabe T. 1997. HTLV-1-associated diseases. *Int J Hematol* 66:257–278. [http://dx.doi.org/10.1016/S0925-5710\(97\)00077-7](http://dx.doi.org/10.1016/S0925-5710(97)00077-7).
- Gessain A, Cassar O. 2012. Epidemiological aspects and world distribution of HTLV-1 infection. *Front Microbiol* 3:388. <http://dx.doi.org/10.3389/fmicb.2012.00388>.
- Watanabe T. 2011. Current status of HTLV-1 infection. *Int J Hematol* 94:430–434. <http://dx.doi.org/10.1007/s12185-011-0934-4>.
- Satake M, Yamaguchi K, Tadokoro K. 2012. Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. *J Med Virol* 84:327–335. <http://dx.doi.org/10.1002/jmv.23181>.
- Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimarui K, Koh KR, Ogata M, Kikuchi H, Sagara Y, Uozumi K, Mochizuki M, Tsukasaki K, Saburi Y, Yamamura M, Tanaka J, Moriuchi Y, Hino S, Kamihira S, Yamaguchi K, Joint Study on Predisposing Factors of ATLDi. 2010. Human T-cell leukemia virus type I (HTLV-1) proviral load

- and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. *Blood* 116:1211–1219. <http://dx.doi.org/10.1182/blood-2009-12-257410>.
8. Takenouchi N, Yamano Y, Usuku K, Osame M, Izumo S. 2003. Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. *J Neurovirol* 9:29–35. <http://dx.doi.org/10.1080/13550280390173418>.
  9. Costa JM, Segurado AC. 2009. Molecular evidence of human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2) infections in HTLV seroindeterminate individuals from Sao Paulo, Brazil. *J Clin Virol* 44:185–189. <http://dx.doi.org/10.1016/j.jcv.2008.12.015>.
  10. Zanjani DS, Shahabi M, Talei N, Afzalaghaee M, Tehrani F, Bazarani R. 2011. Molecular analysis of human T cell lymphotropic virus type 1 and 2 (HTLV-1/2) seroindeterminate blood donors from Northeast Iran: evidence of proviral *tax*, *env*, and *gag* sequences. *AIDS Res Hum Retroviruses* 27:131–135. <http://dx.doi.org/10.1089/aid.2010.0017>.
  11. Watanabe M, Ohsugi T, Shoda M, Ishida T, Aizawa S, Maruyama-Nagai M, Utsunomiya A, Koga S, Yamada Y, Kamihira S, Okayama A, Kikuchi H, Uozumi K, Yamaguchi K, Higashihara M, Umezawa K, Watanabe T, Horie R. 2005. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. *Blood* 106:2462–2471. <http://dx.doi.org/10.1182/blood-2004-09-3646>.
  12. Tanaka G, Okayama A, Watanabe T, Aizawa S, Stuver S, Mueller N, Hsieh CC, Tsubouchi H. 2005. The clonal expansion of human T lymphotropic virus type I-infected T cells: a comparison between seroconverters and long-term carriers. *J Infect Dis* 191:1140–1147. <http://dx.doi.org/10.1086/428625>.
  13. Nagai M, Yamano Y, Brennan MB, Mora CA, Jacobson S. 2001. Increased HTLV-I proviral load and preferential expansion of HTLV-I Tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP. *Ann Neurol* 50:807–812. <http://dx.doi.org/10.1002/ana.10065>.
  14. Kamihira S, Dateki N, Sugahara K, Yamada Y, Tomonaga M, Maeda T, Tahara M. 2000. Real-time polymerase chain reaction for quantification of HTLV-1 proviral load: application for analyzing aberrant integration of the proviral DNA in adult T-cell leukemia. *Int J Hematol* 72:79–84.
  15. Ueno S, Umeki K, Takajo I, Nagatomo Y, Kusumoto N, Umekita K, Morishita K, Okayama A. 2012. Proviral loads of human T-lymphotropic virus type I in asymptomatic carriers with different infection routes. *Int J Cancer* 130:2318–2326. <http://dx.doi.org/10.1002/ijc.26289>.
  16. Kamihira S, Yamano Y, Iwanaga M, Sasaki D, Satake M, Okayama A, Umeki K, Kubota R, Izumo S, Yamaguchi K, Watanabe T. 2010. Intra- and inter-laboratory variability in human T-cell leukemia virus type-I proviral load quantification using real-time polymerase chain reaction assays: a multi-center study. *Cancer Sci* 101:2361–2367. <http://dx.doi.org/10.1111/j.1349-7006.2010.01720.x>.
  17. Sugamura K, Fujii M, Kannagi M, Sakitani M, Takeuchi M, Hinuma Y. 1984. Cell surface phenotypes and expression of viral antigens of various human cell lines carrying human T-cell leukemia virus. *Int J Cancer* 34:221–228. <http://dx.doi.org/10.1002/ijc.2910340213>.
  18. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. 1984. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. *Proc Natl Acad Sci U S A* 81:2534–2537. <http://dx.doi.org/10.1073/pnas.81.8.2534>.
  19. Yamaguchi K, Seiki M, Yoshida M, Nishimura H, Kawano F, Takatsuki K. 1984. The detection of human T cell leukemia virus proviral DNA and its application for classification and diagnosis of T cell malignancy. *Blood* 63:1235–1240.
  20. Uren AG, Mikkers H, Kool J, van der Weyden L, Lund AH, Wilson CH, Rance R, Jonkers J, van Lohuizen M, Berns A, Adams DJ. 2009. A high-throughput Splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. *Nat Protoc* 4:789–798. <http://dx.doi.org/10.1038/nprot.2009.64>.
  21. Sanger F, Nicklen S, Coulson AR. 1977. DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci U S A* 74:5463–5467. <http://dx.doi.org/10.1073/pnas.74.12.5463>.
  22. World Health Organization. 2011. International collaborative study to establish the 3rd WHO international standard for HIV-1 NAT assays. WHO ECBS report 2011 WHO/BS/2011.2178. WHO, Geneva, Switzerland.
  23. Fryer JF, Heath A, Wilkinson DE, Minor PD, The Collaborative Study Group. 2011. Collaborative study to evaluate the proposed 3rd WHO international standard for hepatitis B virus (HBV) for nucleic acid amplification technology (NAT)-based assays. WHO ECBS report 2011 WHO/BS/2011.2170. WHO, Geneva, Switzerland.
  24. Fryer JF, Heath A, Wilkinson DE, Minor PD, The Collaborative Study Group. 2011. Collaborative study to evaluate the proposed 4th WHO international standard for hepatitis C virus (HCV) for nucleic acid amplification technology (NAT)-based assays. WHO ECBS report 2011 WHO/BS/2011.2173. WHO, Geneva, Switzerland.
  25. White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y, Branford S, Muller MC, Beaufils N, Beillard E, Colomer D, Dvorakova D, Ehrencrona H, Goh HG, El Housni H, Jones D, Kairisto V, Kamel-Reid S, Kim DW, Langabeer S, Ma ES, Press RD, Romeo G, Wang L, Zoi K, Hughes T, Saglio G, Hochhaus A, Goldman JM, Metcalfe P, Cross NC. 2010. Establishment of the first World Health Organization international genetic reference panel for quantitation of BCR-ABL mRNA. *Blood* 116:e111–e117. <http://dx.doi.org/10.1182/blood-2010-06-291641>.
  26. Koiwa T, Hamano-Usami A, Ishida T, Okayama A, Yamaguchi K, Kamihira S, Watanabe T. 2002. 5'-Long terminal repeat-selective CpG methylation of latent human T-cell leukemia virus type I provirus *in vitro* and *in vivo*. *J Virol* 76:9389–9397. <http://dx.doi.org/10.1128/JVI.76.18.9389-9397.2002>.
  27. Ishida T, Hamano A, Koiwa T, Watanabe T. 2006. 5' Long terminal repeat (LTR)-selective methylation of latently infected HIV-1 provirus that is demethylated by reactivation signals. *Retrovirology* 3:69. <http://dx.doi.org/10.1186/1742-4690-3-69>.
  28. Firouzi S, Lopez Y, Suzuki Y, Nakai K, Sugano S, Yamochi T, Watanabe T. 2014. Development and validation of a new high-throughput method to investigate the clonality of HTLV-1-infected cells based on provirus integration sites. *Genome Med* 6:46. <http://dx.doi.org/10.1186/gm568>.

ORIGINAL ARTICLE: CLINICAL

## The incidence of adult T-cell leukemia/lymphoma among human T-lymphotropic virus type 1 carriers in Japan

Masahiro Satake<sup>1\*</sup>, Yasuaki Yamada<sup>2\*</sup>, Sunao Atogami<sup>3</sup> & Kazunari Yamaguchi<sup>4</sup>

<sup>1</sup>Central Blood Institute, Japanese Red Cross, Tokyo, Japan, <sup>2</sup>Department of Internal Medicine, Sanwa Central Hospital, Nagasaki, Japan, <sup>3</sup>Department of Internal Medicine, Sasebo Municipal General Hospital, Sasebo, Japan and <sup>4</sup>Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan

### Abstract

Human T-lymphotropic virus type 1 (HTLV-1) is highly endemic in the Kyushu/Okinawa region of Japan. A nationwide investigation verified the frequency of HTLV-1 carriers among first-time blood donors and the occurrence of newly diagnosed adult T-cell leukemia/lymphoma (ATL) cases from 2007 through 2008. After adjusting for differences in capture rate between areas, the age-, sex- and area-specific incidence of ATL among carriers was determined. Annual ATL incidence among 10 000 carriers was 7.7 and 8.7 for the Kyushu and non-Kyushu/Okinawa regions, respectively. The incidence increased sharply for men from their 40s to their 70s, but the rate in females remained unchanged through their 40s to 70s. ATL incidence in middle-aged females was still low, even if female carrier frequency was assumed to be identical to that of males. Patients with ATL in their 60s and 70s will comprise two-thirds of all patients with ATL for the next 15 years in Japan.

**Keywords:** Adult T-cell leukemia/lymphoma, disease incidence, epidemiology, human T-lymphotropic virus type 1, virus carrier

### Introduction

Human T-lymphotropic virus type 1 (HTLV-1) is a causative agent for adult T-cell leukemia/lymphoma (ATL) and infects approximately 15–20 million people worldwide. After a long incubation period, ATL arises in HTLV-1 carriers and has one of the most aggressive clinical courses of the various leukemias. HTLV-1 is highly endemic in southwestern Japan (namely, in the Kyushu region and Okinawa Prefecture), the Caribbean Islands, regions of South America and tropical Africa [1,2]. Detailed data on ATL incidence among HTLV-1 carriers in the whole of Japan were published in 1990 [3]. There has been no systematic study of ATL incidence among carriers since then, although records of patients with ATL were collected biennially until 1997 [4]. In 2008, a new nationwide study was initiated to investigate

HTLV-1 prevalence among blood donors and the incidence of ATL. The study verified that the number of HTLV-1 carriers was 1.08 million in the whole of Japan and has increased outside the Kyushu region [5], indicating that the issue of HTLV-1 carriers and ATL development has to be considered nationwide in Japan. That study also collected records of patients with ATL who were newly diagnosed during 2 years (2007 and 2008), yielding estimates for the prevalence and incidence of patients with ATL in relation to geographic area and patient age [6].

Progress continues to be made in characterizing the molecular mechanisms of gene alterations, signaling deregulation and cell cycle disorder in HTLV-1-infected cells [7,8]. However, the etiologic factors that promote transition to the transformed leukemic state, whether biologic or socioeconomic, remain unknown. In contrast, the environmental conditions that contribute to the occurrence of carriers and hence patients with ATL are relatively clear from the public health point of view: the routes of HTLV-1 infection are well defined (breastfeeding, blood transfusion and sexual behavior); measures for preventing HTLV-1 transmission are well established (bottle feeding and blood screening); carriers of the virus can be easily identified by testing for anti-HTLV-1 antibodies; and the cost for establishing these strategies can be calculated without much difficulty. Therefore, the introduction of measures effective for the eradication of HTLV-1 transmission might be considered a political matter, requiring a solution that would involve medical facilities, health officials and health authorities nationwide [9,10]. To conduct such organized measures, epidemiologic studies elucidating the exact number and distribution of HTLV-1 carriers and patients with ATL are essential.

In this article, we provide an analysis of HTLV-1 prevalence and ATL incidence in Japan, verifying the incidence of ATL among carriers in relation to geographic area and carrier sex and age.

\*These authors contributed equally to the work.

Correspondence: Masahiro Satake, Central Blood Institute, Japanese Red Cross, 2-1-67, Tatsumi, Koto-ku, Tokyo 135-8521, Japan. Tel: +81-3-5534-7500. Fax: +81-3-5534-7516. E-mail: m-satake@jrc.or.jp

Received 4 July 2014; revised 2 September 2014; accepted 8 September 2014



## Materials and methods

### Nationwide study of HTLV-1 carriers and patients with ATL

An investigation of the frequency of HTLV-1 carriers and patients with ATL in Japan was organized in 2008 with the aid of the Japanese Ministry of Health, Labor and Welfare. Methods used and results for the number of HTLV-1 carriers have been described in detail elsewhere [5]. Briefly, we examined the number of individuals positive for anti-HTLV-1 antibody with a confirmatory immunofluorescence test among first-time blood donors during the 2 years from 2007 to 2008. Based on the frequency obtained, we calculated the number of HTLV-1 carriers in categories defined by gender, age and geographic area. The study team also collected the number of patients with ATL newly registered during this 2-year period [6]. Almost one-third of medical institutions with hematologic faculties in Japan ( $n = 156$ ) participated in the investigation. The results indicated a mean annual ATL occurrence of 455 in those institutions. The investigation included a survey for newly registered patients with B-cell non-Hodgkin lymphoma (B-NHL), which served as an internal control (see below).

### Capture rate for patients with B-NHL and ATL in the survey

Our survey likely captured only a subset of the population of patients with ATL, given that only one-third of medical institutions with hematological faculties participated in this study. The frequency of participation by medical facilities differed greatly among areas. The distribution of HTLV-1 carriers, moreover, is geographically biased; nearly half of the carriers dwell in the southwestern region of Japan [5]. These factors would have compromised the precise enumeration of patients with ATL if the observed numbers for ATL were directly extrapolated using the ratios of population size or the number of facilities participating. To avoid this problem, we collected data for patients with B-cell non-Hodgkin lymphoma (B-NHL) as well. It is generally accepted that the frequency of B-NHL occurrence is independent of geography in Japan [11,12]. The number of patients with B-NHL in an area, therefore, is expected to correlate with the size of the population of the area studied.

The statistics for cause of death published by the Japanese Ministry indicate that the annual number of deaths from B-NHL has remained constant over the past 3 years, with a mean value of 9020 [6]. Considering the malignancy of the diseases included in this disease category, the number of annual occurrences of B-NHL is expected to be similar to that of deaths from the disease. We thus estimated the B-NHL incidence in a given area by allocating the total number of deaths in Japan (9020) based on the proportion of the population of a given area to that of the whole of Japan. Comparing the expected number and the observed number in a given area, we calculated the capture rate of B-NHL occurrence in each region covered by this survey. Applying this capture rate to the observed number of patients with ATL, we deduced the number of patients with ATL that would occur in each area.

### Estimation of sex-, age- and area-specific ATL occurrence and future occurrence of patients with ATL

The number of patients with ATL is known to be exceptionally high in Okinawa and all prefectures in the Kyushu region, but very low in other areas. Therefore, figures for ATL were deduced for the geographic areas of Okinawa Prefecture, each of the seven individual prefectures in the Kyushu region, the Kyushu region (all seven prefectures combined) and all non-endemic regions combined (non-Okinawa/Kyushu region) (Figure 1). The total of the number from each area that was deduced using the capture rate described above was defined as that expected to occur in a year in the whole of Japan. We assigned the total number obtained to each age category based on the proportion of observed ATL incidence among age categories. Age category was defined by dividing the 0–99 age-span into 10-year intervals. ATL incidence in an age category was defined as the proportion of the deduced number of patients with ATL among HTLV-1 carriers in the age category. Cumulative lifetime frequency of ATL incidence as expressed by percent was obtained by summing the decennial incidences for ages 0–79 years and multiplying the total by 10.

Using the projected estimates for the number of HTLV-1 carriers that have been published [5] and the ATL incidences in age categories obtained in this study, we calculated the number of cases of ATL expected to occur in the next 15 years.

### Statistical analysis

Data were analyzed using SSRI software (Excel Statistics ver. 8; Social Survey Research Information, Tokyo, Japan) for Windows (Microsoft Excel 2007; Tokyo, Japan). Statistical analysis was performed using the  $\chi^2$  test.  $p$ -Values of less than 0.05 were considered significant.

## Results

We first evaluated the B-NHL capture rate in each area studied. We allocated the annual number of deaths from



Figure 1. Geographic areas of Japan covered in this article.

Table I. Survey for B-cell non-Hodgkin lymphoma.

	B-NHL observed*	Population (thousand)	Population ratio	B-NHL expected†	B-NHL capture rate‡ (95% CI)
Whole country	3582	127 771	1	9020	0.397 (0.387-0.407)
All regions except Kyushu/Okinawa	2870.5	113 107	0.8852	7985	0.359 (0.349-0.370)
Kyushu region§	704	13 295	0.1040	939	0.750 (0.722-0.777)
Fukuoka	265	5055	0.0396	357	0.742 (0.697-0.788)
Saga	31.5	861	0.0067	61	0.518 (0.391-0.642)
Nagasaki	125.5	1460	0.0114	103	1.218
Oh-ita	30.5	1205	0.0094	85	0.359 (0.257-0.461)
Kumamoto	63.5	1832	0.0143	129	0.491 (0.406-0.579)
Miyazaki	68.5	1146	0.0090	81	0.847 (0.767-0.924)
Kagoshima	119.5	1737	0.0136	123	0.975 (0.942-1.001)
Okinawa	7.5	1371	0.0107	97	0.078 (0.024-0.130)

B-NHL, B-cell non-Hodgkin lymphoma; CI, confidence interval.

\*Average annual number of patients with B-NHL observed in 2008 and 2009.

†Expected annual number of patients with B-NHL assuming 9020 deaths from B-NHL in whole country per annum.

‡Ratio of number of observed patients with B-NHL to that of expected patients with B-NHL.

§Kyushu region includes prefectures of Fukuoka, Saga, Nagasaki, Oh-ita, Kumamoto, Miyazaki and Kagoshima.

B-NHL (9020) among the defined areas according to the proportion of the population in each of the areas studied. For example, as the population of Fukuoka Prefecture accounts for 3.96% of the Japanese population, the expected annual incidence of B-NHL in the area was calculated to be 357 ( $9020 \times 0.0396$ ) (Table I). Because the present study identified 265 patients with B-NHL in Fukuoka, the B-NHL capture rate in Fukuoka was determined to be 0.742 (265/357). Assuming that we identified patients with ATL with the same capture rate as for B-NHL in this area, the expected number of new patients with ATL in Fukuoka was calculated to be 76 (56.5/0.742), with the observed number of patients being 56.5 (Table II). Compared with the estimated carrier number in Fukuoka (102 700) [5], the annual incidence for ATL among carriers in Fukuoka Prefecture was calculated to be 0.074% (76/102 700). Using the same method, we deduced the annual occurrence of ATL cases and ATL incidence among carriers for each of the defined areas (Table II).

The numbers for expected ATL occurrence in Okinawa Prefecture, the Kyushu region as the total of those in the seven individual prefectures, and the non-Okinawa/Kyushu region were 148, 325 and 510 per annum, respectively. In Okinawa

Prefecture, however, only two institutions participated in this study, and reported only 15 and 23 cases for B-NHL and ATL, respectively, during the study period. This yielded wide confidence intervals (CIs) for both the B-NHL capture rate and annual ATL incidence. We therefore described the total number of patients with ATL as being 835 occurring annually in the whole of Japan excluding Okinawa Prefecture (Table II).

The annual incidence of ATL among 10 000 HTLV-1 carriers in Okinawa was 21.8, and in the individual prefectures in the Kyushu region the annual incidence ranged between 6.0 and 9.0. Thus, although the rate in Okinawa was significantly higher than any of those in the prefectures in Kyushu ( $p < 0.01$ ), it had a broad CI, as explained above. The rate in the Kyushu region, 7.7, was not statistically different from that in the combined non-Okinawa/Kyushu region (8.7).

The age distribution of HTLV-1 carriers and ATL incidence among carriers are shown in Figures 2(a) and 2(b) by adjusting the total number of ATL occurrences to 983 per annum including the number for Okinawa. The incidence increases sharply for men in their 40s, peaks in their 70s, and decreases sharply thereafter. The rate also increases for women in

Table II. Survey for adult T-cell leukemia/lymphoma.

	ATL observed†	ATL expected‡	Number of HTLV-1 carriers (thousand)	Annual ATL incidence per 10 000§ (95% CI)
Whole country	455	(983)*	1078.7	—
Whole country except Okinawa	443.5	835*	1010.7	8.3 (7.9-8.8)*
All regions except Kyushu/Okinawa	183	510	586.1	8.7 (8.4-8.9)
Kyushu region¶	260.5	325*	424.5	7.7 (7.1-8.6)*
Fukuoka	56.5	76	103.1	7.4 (7.0-7.9)
Saga	6.5	13	18.4	7.1 (5.5-9.0)
Nagasaki	58	48	55.4	8.7
Oh-ita	14.5	40	44.6	9.0 (7.1-12.7)
Kumamoto	15.5	32	46.4	6.9 (5.8-8.2)
Miyazaki	27.5	32	53.5	6.0 (5.6-6.7)
Kagoshima	82	84	103.1	8.1 (7.9-8.4)
Okinawa	11.5	148	68.0	21.8 (13.0-70.0)

ATL, adult T-cell leukemia/lymphoma; B-NHL, B-cell non-Hodgkin lymphoma; CI, confidence interval; HTLV-1, human T-lymphotropic virus type 1.

\*Cumulative sum.

†Average annual number of patients with ATL observed in 2008 and 2009.

‡Expected annual number of patients with ATL deduced using B-NHL capture rate.

§Annual ATL incidence among 10 000 HTLV-1 carriers.

¶Kyushu region includes the prefectures of Fukuoka, Saga, Nagasaki, Oh-ita, Kumamoto, Miyazaki and Kagoshima.




Figure 2. Sex-specific HTLV-1 carriers and ATL incidence in relation to age. Solid and broken lines indicate data for females and males, respectively (a-d). (a, b) Data obtained in this study: (a) carrier number, (b) ATL incidence among carriers (percent per annum). (c, d) Data deduced from calculations assuming that the carrier rate in females is identical to that in males: (c) carrier number, (d) ATL incidence among carriers (percent per annum). ATL incidence for females is higher in their 40s and lower in their 60s to 80s compared to males.

their 40s but remains at approximately the same level until it decreases in their 70s. The rate is significantly higher in females than in males in their 40s ( $p < 0.01$ ), whereas it is significantly lower in females than in males in their 50s to 80s ( $p < 0.01$ ). Cumulative lifetime incidence of ATL at the age of 79 was 7.2% and 4.2% for male and female carriers, respectively.

It has been argued that ATL occurs almost exclusively among carriers who acquired HTLV-1 infection during their neonatal period or infancy [13,14], and that horizontal transmission after adolescence occurs preferentially from males to females [15-17]. Adult female carriers, therefore, include a considerable proportion of individuals who acquired infection horizontally and thus have little possibility of developing ATL, which might correspond to the lower ATL incidence in females in their 50s to 80s. To examine this possibility, we recalculated the female carrier number by applying the male carrier rate to the female population in each age category and then recalculated the ATL incidence in females. Based on this adjustment, the total number of female carriers is predicted to decrease by 27.1% (from 667 000 to 486 000) for the whole of Japan [Figure 2(c)]. Using this recalculated carrier number, the adjusted ATL incidences for female carriers are predicted to increase but still

show differences from those for males [Figure 2(d)]: rates for females are significantly higher in their 40s and lower in their 60s to 80s ( $p < 0.01$  for all comparisons).

To estimate the number of patients with ATL expected in the future, we applied the ATL incidence in each age category to the estimated number of HTLV-1 carriers in each age category [5] for the next 15 years in Japan. We thus expect that the number of patients with ATL will decrease continuously from 940 in 2012 to 530 in 2027 (Figure 3). Patients in their 60s and 70s are expected to account for the increasing plurality (27% and 39%, respectively) of patients during the next 15 years.

## Discussion

We evaluated the incidence of ATL among HTLV-1 carriers in the categories defined by sex and age of carriers and geographic area in Japan. To compensate for the geographic variation in participation frequency by medical facilities, we normalized values using the B-NHL capture rate for each area, given that the B-NHL incidence in Japan appears to be independent of geography [11,12]. This strategy of data collection, which was previously adopted by Tajima [3], is essential, particularly for the epidemiologic study of




Figure 3. Projected ATL occurrence over the next 15 years. Bars show the expected number of patients with ATL for each 10-year age category.

a phenomenon with geographic clustering of subjects. We also assumed that the number of cases of disease is similar to that of deaths for B-NHL. Comparing the total number of observed B-NHL cases with the average annual number of B-NHL deaths registered nationwide, the B-NHL capture rate in this study was calculated to be 39.7%, a figure reflecting the data collection efficiency of this study. The capture rate was higher in the Kyushu region (0.750) than in non-Kyushu regions (0.359), which might have resulted from greater interest in an HTLV-1-related study among physicians in the endemic area, Kyushu, than among physicians in the non-endemic area.

Annual occurrence of ATL as the total in seven individual prefectures in the Kyushu region and non-Kyushu/Okinawa region was deduced to be 835 (95% CI, 795–887). The number for Okinawa Prefecture was not included in this calculation because of the wide CI (95% CI, 88–476). If, however, the number for Okinawa is added, the total number of cases of ATL in the whole of Japan amounts to around 1000, which is close to the number of deaths from ATL reported by the Japanese Ministry of Health, Labor and Welfare (1075 and 1048 in 2007 and 2008, respectively) [18]. This could support the adequacy of the estimation of ATL occurrence based on the B-NHL capture rate in the present study. Thirty-nine percent of patients with ATL were expected to be found in the Kyushu region, and more than 350 were expected in the metropolitan areas of Tokyo, Osaka and Nagoya combined (data not shown).

We did not detect a significant difference in ATL incidence among carriers when comparing Kyushu to non-Okinawa/Kyushu regions, despite the large differences in HTLV-1 prevalence. This result suggests that local environmental factors that may influence ATL development are shared between these areas. The ATL incidence in Okinawa was shown to be more than twice as high as those in other regions, including the Kyushu region, which is geographically proximal to Okinawa. The transcontinental HTLV-1 subgroup (subgroup A) accounts for 20–35% of virus infecting residents in Okinawa, but for very few cases in other regions of Japan, including Kyushu, where the Japanese subgroup (subgroup B)

predominates [19,20]. The ATL-causative potency of subgroup A might be higher than that of subgroup B, although there is, to our knowledge, no published data showing distinguishable differences in ATL incidence between HTLV-1 variants. Background genetic diversity including HLA in carriers also may contribute to differences in ATL incidence [21–23]. In fact, several genome-wide association studies have verified a considerable difference in the genetic background between residents of Okinawa and mainland Japan [24,25]. Comorbidity or differences in lifestyle, socio-economic status and natural environment also may play a role [26–28].

Although these questions are worthy of inquiry, we are, for the present study, limited in the data collection we can do in the Okinawa region. We estimated annual ATL incidence on the basis of B-NHL capture rate. Accordingly, the estimate likely becomes less confident when the number of observed cases of B-NHL decreases. This is the case for Okinawa, where small numbers of cases were reported for B-NHL and ATL during the study period. Future study participation by a larger number of medical institutions and physicians in Okinawa will be needed to draw conclusions on geographic differences in ATL incidence among carriers.

Another limitation of this study is that all demographic data on ATL incidence presented in this article were deduced using, as the denominator, the HTLV-1 carrier number determined among blood donors. However, the HTLV-1 prevalence among blood donors often is reduced compared to values obtained in other populations, such as pregnant women, outpatients, inpatients or even local residents [29,30]. Therefore, the actual numbers of HTLV-1 carriers for each demographic category are expected to be greater than those used in this study. This effect is expected to lessen the actual ATL incidence and lifetime incidence compared to the results derived in this article.

Figure 2 shows that the ATL incidence rate starts to increase for patients in their 30s and peaks in their 70s before subsequently decreasing [3,31]. This trend was seen for both sexes. The decreased incidence in very elderly patients may reflect comorbidity with other age-related diseases such as cardiovascular disease or malignancy, such that those other diseases are registered as the cause of death. Alternatively, carriers with more intrinsic risk factors for ATL might have already developed the disease before their 80s, effectively selecting for living carriers in their 80s and 90s with low risk of developing ATL.

Another finding in this study was that ATL incidence in males increased with age, with peak values observed among men in their 70s; in contrast, incidences were largely unchanged in women from their 40s to 80s. The rate in males in their 70s was almost twice as high as that for females in their 70s. This sex-specific change of incidence with age was previously documented in the study conducted in Ehime Prefecture [31]. As explained above, carriers who acquired infection via horizontal transmission after adolescence are believed to be devoid of risk for ATL development [13,14]. Assuming that vertical transmission occurs equally for male and female children and that horizontal transmission occurs preferentially from males to females, we recalculated

the number of female carriers by applying the male HTLV-1 prevalence to the female population, and then used this adjusted value to reevaluate ATL incidence. This is a strategy that had previously been employed by Tokudome *et al.* [32]. This modification permitted the comparison of sex-specific ATL incidence mainly among carriers who nominally acquired infection vertically, although some proportion of male carriers might also have been infected horizontally. The recalculated ATL incidence for females was increased by this assumption, but the significant differences between sexes remained valid except for patients in their 50s. Thus, male to female transmission of HTLV-1 with proposed reduced risk for future ATL development does not fully explain the lower ATL incidence observed in middle-aged female carriers [32].

The low ATL incidence peculiarly found among females in their 50s to 70s may suggest that women in their 50s to 70s might have had some condition around birth that decreased the risk of ATL development. However, it is difficult to envision such a condition that would have affected only the female population. Sex-specific differences in immune surveillance potency or tumorigenicity may affect the incidence. It was reported that men were significantly less likely than women to have reduced reactivity to purified protein derivative among HTLV-1-negative individuals, whereas this gender difference was not apparent among HTLV-1 carriers [33]. Habitual smoking or alcohol intake, both of which are seen more frequently among males, may also increase their risk of developing ATL. A significant increase in HTLV-1 viral load in subjects with moderate alcohol consumption has been described [34]. Gender differences in lung and gastric cancer incidence and mortality have been attributed to the higher rate of smoking and drinking in males compared to females [35,36]. Alternatively, the low incidence of ATL specifically found among females through their 50s to 70s might reflect the influence of sex hormones or menopausal status on disease development. To our knowledge, studies have rarely mentioned the effect of sex hormones on the molecular mechanism described for ATL development [37–39]. It will be important to examine any possibility of sex differences in the molecular or cellular mechanism(s) of ATL development.

Previous work has shown that the lifetime ATL incidence is between 2 and 5% [13,31,32,40] among carriers. The result in our study, 5.2% for both sexes combined, is in line with reported values. The rate for men (7.2%) was higher than that for women (4.2%), which could partly be explained by the hypotheses described above, namely, the absence of ATL development among horizontally infected carriers and preferential horizontal transmission of HTLV-1 from men to women. These views, however, are based on relatively small cohort studies and deserve verification by a nationwide cohort study wherein seroconverted individuals are followed for life.

Our analysis predicts that the number of patients with ATL will decrease continuously over the next 15 years. In contrast, the proportion of patients in their 60s and 70s will increase year by year, with senior citizens expected to account for two-thirds of new cases detected over the next 15 years. Patients with ATL in their 60s and 70s are generally considered intolerant of aggressive chemotherapy or

hematopoietic stem cell transplant with a conventional myeloablative regimen [41,42]. Recently, hematopoietic stem cell transplant following a reduced intensity conditioning regimen has been proposed for use in elderly patients with hematologic malignancy [43,44]. A clinical trial using interferon- $\alpha$  and zidovudine is also being conducted in Japan [45]. Demonstration of the efficacy and safety of these new approaches for elderly patients with ATL will require further study.

This article defines a nationwide ATL incidence among HTLV-1 carriers by taking into consideration the expected differences in disease capture rate among areas. Among Caribbean and Brazilian carriers, a demographic peak of patients with ATL was reported among those in their 40s, with little sex-specific difference in incidence [46–48], which is in contrast with the data presented in this article. Studies in endemic areas outside of Japan for the occurrence of ATL among carriers by age, sex and geographic area using disease capture rate will be required to understand local factors that contribute to disease pathogenesis.

In conclusion, ATL develops in nearly 1000 HTLV-1 carriers annually in Japan. ATL incidence among carriers is similar among all regions of Japan, including Kyushu. The incidence is significantly lower among middle-aged females compared to males. The number of patients with ATL is predicted to decrease over the course of the next 15 years, but patients in their 60s and 70s will constitute two-thirds of new cases. The development of treatment strategies and supportive interventions applicable to elderly patients is needed.

## Acknowledgements

This work was supported by a grant for the Study Project for Emerging and Re-emerging Infectious Diseases from the Ministry of Health, Labor and Welfare of Japan. The authors gratefully acknowledge the physicians who participated in this study for their efforts in registering patients with ATL and B-NHL.

**Potential conflict of interest:** Disclosure forms provided by the authors are available with the full text of this article at [www.informahealthcare.com/lal](http://www.informahealthcare.com/lal).

## References

- [1] Mueller N. The epidemiology of HTLV-1 infection. *Cancer Causes Control* 1991;2:37–52.
- [2] Manns A, Blattner WA. The epidemiology of the human T-cell lymphotropic virus type I and type II: etiologic role in human disease. *Transfusion* 1991;31:67–75.
- [3] Tajima K. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. *Int J Cancer* 1990;45:237–243.
- [4] The T- and B-cell Malignancy Study Group; Hirose K, Tajima K. The 9th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan. *Jpn J Cancer Clin* 2001;47:341–357. [Japanese]
- [5] Satake M, Yamaguchi K, Tadokoro K. Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. *J Med Virol* 2012;84:327–335.

- [6] Yamada Y, Atogami S, Hasegawa H, et al. Nationwide survey of adult T-cell leukemia/lymphoma (ATL) in Japan. *Rinsho Ketsueki* 2011;52:1765-1771. [Japanese]
- [7] Yamagishi M, Watanabe T. Molecular hallmarks of adult T cell leukemia. *Front Microbiol* 2012;3:334.
- [8] Lairmore MD, Haines R, Anupam R. Mechanisms of human T-lymphotropic virus type 1 transmission and disease. *Curr Opin Virol* 2012;2:474-481.
- [9] Hino S. Establishment of the milk-borne transmission as a key factor for the peculiar endemicity of human T-lymphotropic virus type 1 (HTLV-1): the ATL Prevention Program Nagasaki. *Proc Jpn Acad Ser B Phys Biol Sci* 2011;87:152-166.
- [10] Hino S, Sugiyama H, Doi H, et al. Breaking the cycle of HTLV-1 transmission via carrier mothers' milk. *Lancet* 1987;2:158-159.
- [11] Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. *Pathol Int* 2000;50:696-702.
- [12] Aoki R, Karube K, Sugita Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006. *Pathol Int* 2008;58:174-182.
- [13] Murphy EL, Hanchard B, Figueroa JP, et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. *Int J Cancer* 1989;43:250-253.
- [14] Cleghorn FR, Manns A, Falk R, et al. Effect of human T-lymphotropic virus type I infection on non-Hodgkin's lymphoma incidence. *J Natl Cancer Inst* 1995;87:1009-1014.
- [15] Tajima K, Tominaga S, Suchi T, et al. Epidemiological analysis of the distribution of antibody to adult T-cell leukemia-virus-associated antigen: possible horizontal transmission of adult T-cell leukemia virus. *Jpn J Cancer Res* 1982;73:893-901.
- [16] Kajiyama W, Kashiwagi S, Ikematsu H, et al. Intrafamilial transmission of adult T cell leukemia virus. *J Infect Dis* 1986;154:851-857.
- [17] Murphy EL, Figueroa JP, Gibbs WN, et al. Sexual transmission of human T-lymphotropic virus type I (HTLV-I). *Ann Intern Med* 1989;111:555-560.
- [18] Death rates by sex, age and causes (the condensed list of causes of death for Japan). Available from: [www.e-stat.go.jp/SG1/estat/GL08020102.do?\\_toGL08020102\\_&classID=000001041668&cycleCode=7&requestSender=dsearch](http://www.e-stat.go.jp/SG1/estat/GL08020102.do?_toGL08020102_&classID=000001041668&cycleCode=7&requestSender=dsearch)
- [19] Eguchi K, Fujii H, Oshima K, et al. Human T-lymphotropic virus type 1 (HTLV-1) genetic typing in Kakeroma island, an island at the crossroads of the Ryukyus and Wajin in Japan, providing further insights into the origin of the virus in Japan. *J Med Virol* 2009;81:1450-1456.
- [20] Otani M, Honda N, Xia PC, et al. Distribution of two subgroups of human T-lymphotropic virus type 1 (HTLV-1) in endemic Japan. *Trop Med Health* 2012;40:55-58.
- [21] Sonoda S, Fujiyoshi T, Yashiki S. Immunogenetics of HTLV-I/II and associated diseases. *J Acquir Immune Defic Syndr Hum Retrovirol* 1996;13(Suppl. 1):S119-S123.
- [22] Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, et al. Global epidemiology of HTLV-I infection and associated diseases. *Oncogene* 2005;24:6058-6068.
- [23] Birmann BM, Breen EC, Stuver S, et al. Population differences in immune marker profiles associated with human T-lymphotropic virus type I infection in Japan and Jamaica. *Int J Cancer* 2009;124:614-621.
- [24] Yamaguchi-Kabata Y, Nakazono K, Takahashi A, et al. Japanese population structure, based on SNP genotypes from 7003 individuals compared to other ethnic groups: effects on population-based association studies. *Am J Hum Genet* 2008;83:445-456.
- [25] HUGO Pan-Asian SNP Consortium; Abdulla MA, Ahmed I, Assawamakin A, et al.; Indian Genome Variation Consortium. Mapping human genetic diversity in Asia. *Science* 2009;326:1541-1545.
- [26] Gérard Y, Lepere JF, Pradinaud R, et al. Clustering and clinical diversity of adult T-cell leukemia/lymphoma associated with HTLV-I in a remote black population\* of French Guiana. *Int J Cancer* 1995;60:773-776.
- [27] Levine PH, Manns A, Jaffe ES, et al. The effect of ethnic differences on the pattern of HTLV-I-associated T-cell leukemia/lymphoma (HATL) in the United States. *Int J Cancer* 1994;56:177-181.
- [28] Sonoda S, Li HC, Tajima K. Ethnoepidemiology of HTLV-1 related diseases: ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal. *Cancer Sci* 2011;102:295-301.
- [29] Koga Y, Iwanaga M, Soda M, et al. Trends in HTLV-1 prevalence and incidence of adult T-cell leukemia/lymphoma in Nagasaki, Japan. *J Med Virol* 2010;82:668-674.
- [30] Hlela C, Shepperd S, Khumalo NP, et al. The prevalence of human T-cell lymphotropic virus type 1 in the general population is unknown. *AIDS Rev* 2009;11:205-214.
- [31] Kondo T, Kono H, Miyamoto N, et al. Age- and sex-specific cumulative rate and risk of ATLL for HTLV-1 carriers. *Int J Cancer* 1989;43:1061-1064.
- [32] Tokudome S, Tokunaga O, Shimamoto Y, et al. Incidence of adult T-cell leukemia/lymphoma among human T-lymphotropic virus type I carriers in Saga, Japan. *Cancer Res* 1989;49:226-228.
- [33] Hisada M, Stuver SO, Okayama A, et al. Gender difference in skin reactivity to purified protein derivative among carriers of HTLV-I in Japan. *J Acquir Immune Defic Syndr* 1999;22:302-307.
- [34] Kwaan N, Lee TH, Chafets DM, et al.; HTLV Outcomes Study (HOST) Investigators. Long-term variations in human T lymphotropic virus (HTLV)-I and HTLV-II proviral loads and association with clinical data. *J Infect Dis* 2006;194:1557-1564.
- [35] Mannino DM, Ford E, Giovino GA, et al. Lung cancer mortality rates in birth cohorts in the United States from 1960 to 1994. *Lung Cancer* 2001;31:91-99.
- [36] Zhang J, Zhan Z, Wu J et al. Association among polymorphisms in EGFR gene exons, lifestyle and risk of gastric cancer with gender differences in Chinese Han subjects. *PLoS One* 2013;8:e59254.
- [37] Uozumi K, Uematsu T, Otsuka M, et al. Serum dehydroepiandrosterone and DHEA-sulfate in patients with adult T-cell leukemia and human T-lymphotropic virus type I carriers. *Am J Hematol* 1996;53:165-168.
- [38] LosM, KhazaieK, Schulze-OsthoffK, et al. Human T cell leukemia virus-I (HTLV-I) Tax-mediated apoptosis in activated T cells requires an enhanced intracellular prooxidant state. *J Immunol* 1998;161:3050-3055.
- [39] Tzagarakis-Foster C, Geleziunas R, Lomri A, et al. Estradiol represses human T-cell leukemia virus type 1 Tax activation of tumor necrosis factor- $\alpha$  gene transcription. *J Biol Chem* 2002;277:44772-44777.
- [40] Tajima K, Cartier L. Epidemiological features of HTLV-I and adult T cell leukemia. *Intervirology* 1995;38:238-246.
- [41] Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. *J Clin Oncol* 2009;27:453-459.
- [42] Tanosaki R, Tobinai K. Adult T-cell leukemia-lymphoma: current treatment strategies and novel immunological approaches. *Expert Rev Hematol* 2010;3:743-753.
- [43] Obama K, Utsunomiya A, Takatsuka Y, et al. Reduced-intensity non-T-cell depleted HLA-haploidentical stem cell transplantation for older patients based on the concept of feto-maternal tolerance. *Bone Marrow Transplant* 2004;34:897-899.
- [44] Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. *Blood* 2005;105:4143-4145.
- [45] Tsukasaki K, Tobinai K. Biology and treatment of HTLV-1 associated T-cell lymphomas. *Best Pract Res Clin Haematol* 2013;26:3-14.
- [46] Hanchard B. Adult T-cell leukemia/lymphoma in Jamaica: 1986-1995. *J Acquir Immune Defic Syndr Hum Retrovirol* 1996;13(Suppl. 1):S20-S25.
- [47] Hisada M, Stuver SO, Okayama A, et al. Persistent paradox of natural history of human T lymphotropic virus type I: parallel analyses of Japanese and Jamaican carriers. *J Infect Dis* 2004;190:1605-1609.
- [48] Pombo de Oliveira MS, Matutes E, Schulz T, et al. T-cell malignancies in Brazil. Clinico-pathological and molecular studies of HTLV-I-positive and -negative cases. *Int J Cancer* 1995;60:823-827.



# System Vaccinology for the Evaluation of Influenza Vaccine Safety by Multiplex Gene Detection of Novel Biomarkers in a Preclinical Study and Batch Release Test

Takuo Mizukami<sup>1</sup>, Haruka Momose<sup>1</sup>, Madoka Kuramitsu<sup>1</sup>, Kazuya Takizawa<sup>1</sup>, Kumiko Araki<sup>1</sup>, Keiko Furuhashi<sup>1</sup>, Ken J. Ishii<sup>2,3</sup>, Isao Hamaguchi<sup>1\*</sup>, Kazunari Yamaguchi<sup>1</sup>

**1** Laboratory of Blood and Vaccine safety, Department of Safety Research on Blood and Biologicals, National Institute of Infectious Diseases, Tokyo, Japan, **2** Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation (NIBIO), Osaka, Japan, **3** Laboratory of Vaccine Science, WPI Immunology Frontier Research Center (WPI-IFREC), Osaka University, Osaka, Japan

## Abstract

Vaccines are beneficial and universal tools to prevent infectious disease. Thus, safety of vaccines is strictly evaluated in the preclinical phase of trials and every vaccine batch must be tested by the National Control Laboratories according to the guidelines published by each country. Despite many vaccine production platforms and methods, animal testing for safety evaluation is unchanged thus far. We recently developed a systems biological approach to vaccine safety evaluation where identification of specific biomarkers in a rat pre-clinical study evaluated the safety of vaccines for pandemic H5N1 influenza including *Irf7*, *Lgals9*, *Lgalsbp3*, *Cxcl11*, *Timp1*, *Tap2*, *Psmb9*, *Psme1*, *Tapbp*, *C2*, *Csf1*, *Mx2*, *Zbp1*, *Ifrd1*, *Trafd1*, *Cxcl9*,  $\beta$ 2m, *Npc1*, *Ngr1* and *Irf47*. The current study evaluated whether these 20 biomarkers could evaluate the safety, batch-to-batch and manufacturer-to-manufacturer consistency of seasonal trivalent influenza vaccine using a multiplex gene detection system. When we evaluated the influenza HA vaccine (HAV) from four different manufactures, the biomarker analysis correlated to findings from conventional animal use tests, such as abnormal toxicity test. In addition, sensitivity of toxicity detection and differences in HAVs were higher and more accurate than with conventional methods. Despite a slight decrease in body weight caused by HAV from manufacturer B that was not statistically significant, our results suggest that HAV from manufacturer B is significantly different than the other HAVs tested with regard to *Lgals3bp*, *Tapbp*, *Lgals9*, *Irf7* and *C2* gene expression in rat lungs. Using the biomarkers confirmed in this study, we predicted batch-to-batch consistency and safety of influenza vaccines within 2 days compared with the conventional safety test, which takes longer. These biomarkers will facilitate the future development of new influenza vaccines and provide an opportunity to develop *in vitro* methods of evaluating batch-to-batch consistency and vaccine safety as an alternative to animal testing.

**Citation:** Mizukami T, Momose H, Kuramitsu M, Takizawa K, Araki K, et al. (2014) System Vaccinology for the Evaluation of Influenza Vaccine Safety by Multiplex Gene Detection of Novel Biomarkers in a Preclinical Study and Batch Release Test. PLoS ONE 9(7): e101835. doi:10.1371/journal.pone.0101835

**Editor:** Sang-Moo Kang, Georgia State University, United States of America

**Received:** March 10, 2014; **Accepted:** June 11, 2014; **Published:** July 10, 2014

**Copyright:** © 2014 Mizukami et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability:** The authors confirm that all data underlying the findings are fully available without restriction. All data are included within the paper.

**Funding:** This work was supported by Grants-in-Aid from Ministry of Health, Labor, and Welfare of Japan (201132001 and 201208036, respectively). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* Email: 130hama@nih.go.jp

## Introduction

Vaccination is a beneficial and universal tool to prevent infectious disease [1]. Because most vaccines are derived from inactivated virus, bacteria or toxoids, contamination by incomplete inactivation can cause serious adverse events. Thus, historically, the safety of vaccines is strictly regulated by law and each batch of vaccine must be tested by the National Control Laboratories according to the guidelines published in each country, e.g. the European Pharmacopeia, United States Pharmacopeia and World Health Organization guidelines [2]. After the diphtheria toxoid (DT) immunization incident in Japan in 1950 that caused the death of 68 children and illness in over 600 infants owing to contamination by incomplete inactivation of DT [3], the abnormal toxicity test (ATT) (also known as general safety test) was introduced to the Japanese guidelines. This stated that the minimum requirement of biological products (MRBP) and all

inactivated vaccines and toxoids was mandatory safety evaluation by ATT and other specific toxicity tests.

Influenza vaccine is one of the most widely used commercially available vaccines worldwide for preventing seasonal influenza and its complications. Influenza virus vaccine is mainly produced using embryonated fertilized chicken eggs and inactivated with formaldehyde. Whole particle influenza virus vaccine [WPV] was first licensed as an influenza vaccine in the US in 1945 [4] and is still used in some countries. Although WPV contains all the components of the influenza virus and induces strong immunity in the vaccinated individual, a high incidence of adverse events, including local reactions at the site of injection and febrile illness, particularly among children have been reported [5,6]. Thus, most recent vaccines manufactured since the 1970s have been subvirion vaccines. The subvirion influenza HA vaccine [HAV] showed a marked reduction of pyrogenicity compared with WPV [7]. The trivalent influenza vaccine [TIV] is a recently developed subvirion

influenza vaccine with components selected and updated each year to protect against one of the three main groups of circulating influenza virus strains in humans. TIV may be administered every year. Vaccine adjuvant, e.g. alum, MF59 and AS03, was also used to enhance immunity in preparation for the H5N1 pandemic [8]. To improve immunogenicity and reduce toxicity in addition to batch-to-batch quality assurance of influenza vaccine, seed lot systems, recombinant DNA technology, as well as animal and insect cell culture inactivated vaccine production systems were introduced. Despite the increase in many vaccine production platforms, adjuvants, additives and vaccine types, safety evaluation tests in the preclinical phase and batch release have been unchanged in most countries, including in Japan.

We previously reported that improved AIT could evaluate and assure the batch-to-batch consistency of vaccines more strictly compared with conventional methods [9]. In addition, we recently introduced a system biological approach to vaccine safety evaluation and demonstrated that specific biomarkers could be used to evaluate batch-to-batch consistency and safety of vaccines to diphtheria-pertussis-tetanus (DPT) [10,11] and Japanese encephalitis virus (JEV) [12]. Most recently, we showed that a system biological approach could evaluate the safety of pandemic H5N1 influenza vaccine [13]. We found 20 biomarkers for the evaluation of batch-to-batch consistency and the safety of H5N1 vaccine compared with HAV.

In this study, we tested whether these biomarkers could evaluate batch-to-batch consistency and the safety of seasonal HAV, as well as adjuvanted whole virion-derived influenza vaccine, using a multiplex gene detection system. This method might facilitate the evaluation of batch-to-batch consistency of HAV and reduce the time required for batch release compared with conventional AIT. These biomarkers will help the future development of *in vitro*

methods to evaluate vaccine safety as an alternative to animal testing.

## Materials and Methods

### 1. Animals and Ethics statement

Eight-week-old male Fischer (F334/N) rats weighing 160–200 g were obtained from SLC (Tokyo, Japan). All animals were housed in rooms maintained at  $23 \pm 1^\circ\text{C}$ , with  $50 \pm 10\%$  relative humidity, and 12-h light/dark cycles for at least 1 week prior to the test use. All animal experiments were performed according to the guidelines of the Institutional Animal Care and Use Committee of the National Institute of Infectious Diseases (NIID), Tokyo, Japan. The study was approved by the Institutional Animal Care and Use Committee of NIID.

### 2. Vaccines


The following vaccines were used in this study: (1) PDv: inactivated monovalent A/H5N1 whole-virion influenza vaccine (derived from NIBRG-14: A/Vietnam/1194/2004) adjuvanted with aluminum hydroxide, containing 30  $\mu\text{g}$  HA/ml; (2) WPv: inactivated whole trivalent influenza vaccine (A/Newcaledonia/20/99 (H1N1), A/Hiroshima/52/2005 (H3N2), and B/Malaysia/2506/2004); HAV: trivalent HA influenza vaccine (A/Solomon Island/3/2006 (H1N1), A/Hiroshima/52/2005 (H3N2), and B/Malaysia/2506/2004), containing 30  $\mu\text{g}$  HA/ml each strain. For evaluation of commercially distributed HAV in Japan, we used trivalent HA influenza vaccine (A/Solomon Island/3/2006 (H1N1), A/Hiroshima/52/2005 (H3N2) and B/Malaysia/2506/2004), containing 30  $\mu\text{g}$  HA/ml per strain. PDv and WPv were produced, and manufactured by the Chemo-Scro-Therapeutic Research Institute, Kaketsuken (Kumamoto, Japan). Licensed and authorized HAVs were purchased from four different manufactur-

**Table 1.** Biomarkers to evaluate influenza vaccine safety.

Official Symbol	Official Full Name	Gene ID
<i>Irf7</i>	Interferon regulatory factor 7	293624
<i>Lgals9</i>	Lectin, galactoside-binding, soluble, 9	25476
<i>Lgalsbp3</i>	Lectin, galactoside-binding, soluble, 3 binding protein	245955
<i>Cxcl11</i>	Chemokine (C-X-C motif) ligand 11	305236
<i>Timp1</i>	TIMP metalloproteinase inhibitor 1	116510
<i>Tap2</i>	Transporter 2, ATP-binding cassette, sub-family B	24812
<i>Psmb9</i>	Proteasome (prosome, macropain) subunit, beta type, 9	24967
<i>Psmc1</i>	Proteasome (prosome, macropain) activator subunit 1	29630
<i>Tapbp</i>	TAP binding protein (tapasin)	25217
<i>C2</i>	Complement component 2	24231
<i>Csf1</i>	Colony stimulating factor 1 (macrophage)	78965
<i>Mx2</i>	Myxovirus (influenza virus) resistance 2	286918
<i>Zbp1</i>	Z-DNA binding protein 1	171091
<i>Irfd1</i>	Interferon-related developmental regulator 1	29596
<i>Traf1</i>	TRAF type zinc finger domain containing 1	114635
<i>Cxcl9</i>	Chemokine (C-X-C motif) ligand 9	246759
<i><math>\beta</math>2m</i>	Beta-2 microglobulin	24223
<i>Npc1</i>	Niemann-Pick disease, type C1	266732
<i>Ngfr</i>	Nerve growth factor receptor	24596
<i>Ifi47</i>	Interferon gamma inducible protein 47	246208

doi:10.1371/journal.pone.0101835.t001






**Figure 1. Optimization of QGP in influenza vaccine safety evaluation.** A) Gene expression of *Actb*, *Gapdh*, *B2m* and *C2* and B) biomarkers, in 0.2, 2 and 20 ng RNA-containing samples from SA- and WPv-treated rat lungs. Relative expression levels of the *Gapdh* gene are indicated. SA: saline, WPv: Whole particle virion influenza vaccine. doi:10.1371/journal.pone.0101835.g001

ers [HAv (Lot L03A) from Kaketsuken (Kumamoto), HAv (Lot 309) from Kitasato Institute (Saitama), HAv (Lot 343-A) from Denka Seiken Co., Ltd. (Tokyo), HAv (Lot HA082D) from Biken (Kagawa)] in Japan. All vaccines complied with the MRBP in Japan. HAv used in this study was tested and authorized by NCL (National Control Laboratory) for distribution in Japan.

### 3. Abnormal toxicity test

ATT was performed according to the MRBP [http://www.nih.gov/jp/niid/en/mrbp-e.html] using rats with a slight modification.

Each 5 ml of vaccine was intra-peritoneally (*i.p.*) injected into rats. Five milliliters of saline (SA) (Otsuka normal saline; Otsuka Pharmaceutical Factory Inc., Naruto, Tokushima, Japan) was *i.p.* injected as a control. One day after the injection, rat body weight was measured and peripheral blood was collected. The number of white blood cells was counted with a hemocytometer (Nihon Kohden, Japan).




**Figure 2. Validation of QGP with real-time PCR methods.** A) QGP result was validated with real-time PCR methods. Bar graph indicates the real-time PCR results and dot blot indicates QGP results. B) Biomarkers were classified into three grades according to the relative expression level compared with WPv-treated rats. doi:10.1371/journal.pone.0101835.g002

#### 4. RNA preparation

One day after injection, rats were sacrificed to obtain whole lung tissues. Organs were immediately frozen in liquid nitrogen for storage. Thawed tissue was homogenized and mixed with an Isogen reagent (Nippon Gene, Tokyo, Japan). Total RNA was prepared from the lysate in accordance with the manufacturer's instructions. Poly (A)+ RNA was prepared from total RNA with a Poly (A) Purist Kit (Ambion, Austin, TX), according to the manufacturer's instructions.

#### 5. Quantitative RT-PCR analysis

Poly (A)+ RNA was used to synthesize first-strand cDNA using a First-strand cDNA Synthesis Kit (Life Science Inc., St. Petersburg, FL), according to the manufacturer's instructions. Expression levels of biomarkers (Table 1) were analyzed by real-time polymerase chain reaction (PCR) using a 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) with 7500 Fast System SDS Software Version 1.3. cDNA was amplified for real-time PCR using SYBR Green I (Molecular Probes Inc.) to detect the PCR products. One microliter of 6-fold diluted cDNA was



**Figure 3. Evaluation of seasonal influenza vaccine with conventional animal safety test.** A) The abnormal toxicity test was performed according to the Minimum Requirements of Biological Products. Each 5 ml vaccine was *i.p.* injected into rats, the body weight measured and lung tissues collected at day 1 after injection. B) Body weight change at day 1 after injection. NT: nontreated rat, SA: saline, PDv: pandemic H5N1 whole virion-derived vaccine with alum adjuvant, WPv: whole particle virion influenza vaccine, HA<sub>v</sub>: influenza HA vaccine, Man: manufacturer. doi:10.1371/journal.pone.0101835.g003

used in a 20- $\mu$ l final volume reaction containing 10  $\mu$ l SYBR Green PCR Master Mix (Applied Biosystems), and forward and reverse primers were as described previously [13]. The 7500 Fast System was programmed to run an initial polymerase activation step at 95°C for 10 min followed by 40 cycles of denaturation (95°C for 15 s) and extension (60°C for 1 min). Product synthesis was monitored at the end of the extension step of each cycle. Gene expression values were normalized against rat GAPDH.

## 6. QuantiGene Plex assays

QuantiGene Plex (QGP) assays were performed according to the QuantiGene Plex Reagent System instructions (Panomics Inc., Fremont, CA), as described previously [11]. Briefly, 10  $\mu$ l of starting poly (A)+RNA (50 ng) was incubated for 10 min at 65°C, then mixed with 33.3  $\mu$ l of lysis mixture, 40  $\mu$ l of capture buffer, 2  $\mu$ l of capture beads, and 2  $\mu$ l of the target gene-specific probe set. Probe sets were heated for 5 min prior to use. Each sample mixture was then dispensed into an individual well of a capture plate, sealed with foil tape and incubated at 54°C for 16–20 h. The hybridization mixture was transferred to a filter plate, and the wells were washed three times with 200  $\mu$ l of wash buffer. Signals for the bound target mRNA were developed by sequential hybridization with branched DNA (bDNA) amplifier, and biotin-conjugated label probe, at 48°C for 1 h each. Two washes with wash buffer were used to remove unbound material after each hybridization step. Streptavidin-conjugated phycoerythrin was added to the wells and incubated at room temperature for 30 min. The luminescence of each well was measured using a

Luminex 100 microtiter plate luminometer (Luminex). Two replicate assays measuring RNA directly (independent sampling  $n=6$  for mRNA,  $n=3-5$  for lysate) were performed for all described experiments. The 20 target genes and GAPDH mRNA were quantified, and the ratio of the target genes to GAPDH mRNA was calculated.


## 7. Statistical analysis

Multiple comparisons were performed for SA, PDv, WPv and HA. To determine differences between manufacturers, multiple comparisons were performed for SA and HA from manufacturers A, B, C and D. Statistical analysis was performed in GraphPad Prism 6 (GraphPad Software, La Jolla, CA) using an ordinary one-way analysis of variance test followed by a Tukey multiple comparison test.

## Results

### Optimization of multiple gene detection system, QuantiGene Plex, for safety evaluation of the influenza vaccine

We previously reported that 20 selected genes (Table 1), from 76 differentially expressed genes in adsorbed PDv-treated rats, could be used as biomarkers to evaluate H5N1 influenza vaccine safety compared with other types of influenza vaccine using conventional real-time PCR [13]. To establish faster and more convenient methods to detect these biomarkers in one-step as a new vaccine safety test, we used QuantiGene Plex (QGP)



**Figure 4. Evaluation of seasonal influenza vaccine with QGP.** The relative gene expression levels of the *Gapdh* gene are indicated in each column (grades 1, 2 and 3, respectively). \*Significant difference between B and C. \*\*Significant difference between B, C and D, \*\*\*Significant difference between PD and WPv. doi:10.1371/journal.pone.0101835.g004

technology (Panomics Inc., Fremont, CA). We designed a custom QGP 2.0 assay to enable the measurement of expression levels of

identified biomarkers. The Panomics QGP 2.0 assays provided quantitative measurements of 3 to 80 target RNAs per well by